A 78-year-old man with postoperative recurrence of esophageal cancer was admitted to the hospital due to chest pain and dyspnea. Oral short-acting opioids provided some relief, but chest pain persisted and worsened, leading to the initiation of a transdermal fentanyl patch. However, the patient developed opioid-induced urinary retention, which was treated with a naldemedine, a medication used for opioid-induced constipation and urinary retention. Opioid switching led to recurrent urinary retention, requiring placement of a urinary catheter. The patient ultimately required continuous deep sedation for refractory symptoms and died several days later.
Get full access to this article
View all access options for this article.
References
1.
O'RiordanJA, HopkinsPM, RavenscroftA, et al.Patient-controlled analgesia and urinary retention following lower limb joint replacement: Prospective audit and logistic regression analysis. Eur J Anaesthesiol, 2000; 17(7):431–435.
2.
MercadanteS, FerreraP, CasuccioA. Prevalence of opioid-related dysuria in patients with advanced cancer having pain. Am J Hosp Palliat Care, 2011:28:27–30.
3.
PaisR, LeeP, CrossS, et al.Bladder care in palliative care inpatients: A prospective dual site cohort study. Palliat Med Rep, 2020; 30;1(1):251–258.
4.
RosowCE, GomeryP, ChenTY, et al.Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clin Pharmacol Ther, 2007: 82: 48–53.
5.
RawalN, MölleforsK, AxelssonK, et al.An experimental study of urodynamic effects of epidural morphine and of naloxone reversal. Anesth Analg, 1983; 62(7):641–647.
6.
KanemasaT, KoikeK, TakaseK, et al.Pharmacological profile of naldemedine, a peripherally acting μ-opioid receptor antagonist: Comparison with naloxone and naloxegol. J Pharmacol Exp Ther, 2020; 373:438–444.
7.
MercadanteS. A peripheral opioid antagonist for treating urinary retention induced by opioids: A case report. Palliat Med, 2022; 36:1313–1315.
8.
VerhammeKM, SturkenboomMC, StrickerBH, et al.Drug induced urinary retention: Incidence, management and prevention. Drug Safety, 2008; 31:373–388.
9.
ChenZR, IrvineRJ, SomogyiAA, et al.Mu receptor binding of some commonly used opioids and their metabolites. Life Sci, 1991; 48(22):2165–2171.
10.
HuK, BridgemanMB. Naldemedine (Symproic) for the treatment of opioid-induced constipation. PT, 2018; 43(10):601–627.
11.
TakagiY, OsawaG, KatoY, et al.Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: A retrospective cohort study. BMC Gastroenterol, 2020; 20(1):25.
12.
WebsterLR, NalamachuS, MorlionB, et al.Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: A randomized, double-blind, placebo-controlled phase 3 study. Pain, 2018; 159(5):987–994.
